Dimesna clinical trials
Also written BNP7787.
How each study uses dimesna is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dimesna studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2001 (1)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2010 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
BioNumerik Pharmaceuticals, Inc. (2) · Lantern Pharma Inc. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test dimesna.
- Dec 2026A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaPhase 2 · Lantern Pharma Inc.
Studies
Open first, then newest update. How each study uses dimesna is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaRecruitingPhase 2Lantern Pharma Inc.NCT05456256Written as LP-300
- Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly PaclitaxelCompletedPhase 3BioNumerik Pharmaceuticals, Inc.NCT00039780Written as BNP7787
- Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus CisplatinCompletedPhase 3BioNumerik Pharmaceuticals, Inc.NCT00966914Written as Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel
Given beside what is tested · 1 — dimesna is usual care or a partner of the new treatment
Codes
What other systems call dimesna · ClinicalTrials.gg INT002845
- MeSH (NLM) C0270322,2'-dithiodiethanesulfonic acidConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 230R951Y4DDIMESNAConfirmed FDA, NLM, Wikidata
- Wikidata Q27253698dimesnaConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1365DimesnaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C027032 | 2,2'-dithiodiethanesulfonic acid | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 230R951Y4D | DIMESNA | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27253698 | dimesna | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1365 | Dimesna | One source FDA |
Also registered as 2,2'-dithiodiethanesulfonic acid (UNII 6Q2L2H0POF).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.